Topics

Human medicines European public assessment report (EPAR): Aerivio Spiromax, salmeterol / fluticasone propionate, Pulmonary Disease, Chronic Obstructive,Asthma, Date of authorisation: 18/08/2016, Revision: 2, Status: Withdrawn

11:00 EST 15 Jan 2020 | European Medicines Agency

Human medicines European public assessment report (EPAR): Aerivio Spiromax, salmeterol / fluticasone propionate, Pulmonary Disease, Chronic Obstructive,Asthma, Date of authorisation: 18/08/2016, Revision: 2, Status: Withdrawn

Original Article: Human medicines European public assessment report (EPAR): Aerivio Spiromax, salmeterol / fluticasone propionate, Pulmonary Disease, Chronic Obstructive,Asthma, Date of authorisation: 18/08/2016, Revision: 2, Status: Withdrawn

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Aerivio Spiromax, salmeterol / fluticasone propionate, Pulmonary Disease, Chronic Obstructive,Asthma, Date of authorisation: 18/08/2016, Revision: 2, Status: Withdrawn"

Quick Search

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...